67605-84-9
Chemical Structure
Cer (d18:1/23:0)
- CAS No.: 67605-84-9
- Formula:C41H81NO3
- Molecular Weight:636.10
IUPAC Name: N-((2S,3R,E)-1,3-dihydroxyoctadec-4-en-2-yl)tricosanamide
InChIKey: NAJHAHQNQCNWOP-PUYNVXOJSA-N
SMILES: [C@@H](NC(CCCCCCCCCCCCCCCCCCCCCC)=O)([C@@H](/C=C/CCCCCCCCCCCCC)O)CO
Biological Activity: Cer (d18:1/23:0) is a ceramide (sphingolipid). The level of Cer (d18:1/23:0) increases in coronary heart disease patients exposed to Metformin. The level of Cer (d18:1/23:0) is elevated in Chinese prediabetic and type 2 diabetic patients, and positively correlates with fasting blood glucose levels. Cer (d18:1/23:0) can be used in studies related to coronary heart disease, prediabetes and type 2 diabetes[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cer (d18:1/23:0) | Cer (d18:1/23:0) is a ceramide (sphingolipid). The level of Cer (d18:1/23:0) increases in coronary heart disease patients exposed to Metformin. The level of Cer (d18:1/23:0) is elevated in Chinese prediabetic and type 2 diabetic patients, and positively correlates with fasting blood glucose levels. Cer (d18:1/23:0) can be used in studies related to coronary heart disease, prediabetes and type 2 diabetes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Li X, et al. Association of plasma ceramides with short-term and lifetime risk of MACE in coronary atherosclerotic heart disease patients: a prospective cohort study. BMJ Open. 2025;15(10):e094100. Published 2025 Oct 21. [Content Brief]
- [2]. Gruzdeva O, et al. Effects of metformin on the ceramide profile of adipocytes of local heart fat depots in patients with coronary artery disease[J]. Atherosclerosis, 2024, 395.
- [3]. Yang J, et al. Integrated lipids biomarker of the prediabetes and type 2 diabetes mellitus Chinese patients. Front Endocrinol (Lausanne). 2023;13:1065665. Published 2023 Jan 20. [Content Brief]
